These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 33435908)

  • 41. Treatment of Retinal Vein Occlusion with Ranibizumab in Clinical Practice: Longer-Term Results and Predictive Factors of Functional Outcome.
    Farinha C; Marques JP; Almeida E; Baltar A; Santos AR; Melo P; Costa M; Figueira J; Cachulo ML; Pires I; Silva R
    Ophthalmic Res; 2015; 55(1):10-8. PubMed ID: 26540281
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sustained Benefits of Ranibizumab with or without Laser in Branch Retinal Vein Occlusion: 24-Month Results of the BRIGHTER Study.
    Tadayoni R; Waldstein SM; Boscia F; Gerding H; Gekkieva M; Barnes E; Das Gupta A; Wenzel A; Pearce I;
    Ophthalmology; 2017 Dec; 124(12):1778-1787. PubMed ID: 28807635
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intravitreal Dexamethasone Implant versus Intravitreal Ranibizumab for the Treatment of Macular Edema Secondary to Retinal Vein Occlusion in a Chinese Population.
    Gu X; Yu X; Song S; Dai H
    Ophthalmic Res; 2017; 58(1):8-14. PubMed ID: 28334720
    [TBL] [Abstract][Full Text] [Related]  

  • 44. RANIBIZUMAB FOR RETINAL VEIN OCCLUSION: Predictive Factors and Long-Term Outcomes in Real-Life Data.
    Chatziralli I; Theodossiadis G; Chatzirallis A; Parikakis E; Mitropoulos P; Theodossiadis P
    Retina; 2018 Mar; 38(3):559-568. PubMed ID: 28248827
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of ranibizumab alone versus ranibizumab with targeted retinal laser for branch retinal vein occlusion with macular edema.
    Goel S; Kumar A; Ravani RD; Chandra P; Chandra M; Kumar V
    Indian J Ophthalmol; 2019 Jul; 67(7):1105-1108. PubMed ID: 31238421
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions.
    Pieramici DJ; Rabena M; Castellarin AA; Nasir M; See R; Norton T; Sanchez A; Risard S; Avery RL
    Ophthalmology; 2008 Oct; 115(10):e47-54. PubMed ID: 18708258
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Low frequency ranibizumab versus dexamethasone implant for macular oedema secondary to branch retinal vein occlusion.
    Yuksel B; Karti O; Celik O; Kerci SG; Kusbeci T
    Clin Exp Optom; 2018 Jan; 101(1):116-122. PubMed ID: 28922697
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intravitreal ranibizumab for macular edema secondary to central retinal vein occlusion.
    Risard SM; Pieramici DJ; Rabena MD; Basefsky JC; Avery RL; Castellarin AA; Nasir MA; See RF; Couvillion SS
    Retina; 2011 Jun; 31(6):1060-7. PubMed ID: 21283055
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bevacizumab versus bevacizumab and macular grid photocoagulation for macular edema in eyes with non-ischemic branch retinal vein occlusion: results from a prospective randomized study.
    Callizo J; Atili A; Striebe NA; Bemme S; Feltgen N; Hoerauf H; Bertelmann T
    Graefes Arch Clin Exp Ophthalmol; 2019 May; 257(5):913-920. PubMed ID: 30610424
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X; Li J; Hu X; Yu S; Pan J; Tang S
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intravitreal ranibizumab versus isovolemic hemodilution in the treatment of macular edema secondary to central retinal vein occlusion: twelve-month results of a prospective, randomized, multicenter trial.
    Kreutzer TC; Wolf A; Dirisamer M; Strauss RW; Foerster P; Feltgen N; Pielen A; Hattenbach LO; Kampik A; Priglinger SG
    Ophthalmologica; 2015; 233(1):8-17. PubMed ID: 25502833
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Current Outcomes of Anti-VEGF Therapy in the Treatment of Macular Oedema Secondary to Branch Retinal Vein Occlusions: A Meta-Analysis.
    Spooner K; Hong T; Fraser-Bell S; Chang AA
    Ophthalmologica; 2019; 242(3):163-177. PubMed ID: 31158837
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion.
    Saishin Y; Ito Y; Fujikawa M; Sawada T; Ohji M
    Jpn J Ophthalmol; 2017 Jan; 61(1):67-73. PubMed ID: 27660163
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Visual acuity outcomes and anti-VEGF therapy intensity in macular oedema due to retinal vein occlusion: a real-world analysis of 15 613 patient eyes.
    Ciulla T; Pollack JS; Williams DF
    Br J Ophthalmol; 2021 Dec; 105(12):1696-1704. PubMed ID: 33055088
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The correlation between cytokine levels in the aqueous humor and the prognostic value of anti-vascular endothelial growth factor therapy for treating macular edema resulting from retinal vein occlusion.
    Yong H; Qi H; Yan H; Wu Q; Zuo L
    Graefes Arch Clin Exp Ophthalmol; 2021 Nov; 259(11):3243-3250. PubMed ID: 34059950
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and Safety of Ranibizumab in Asian Patients with Branch Retinal Vein Occlusion: Results from the Randomized BLOSSOM Study.
    Wei W; Weisberger A; Zhu L; Cheng Y; Liu C;
    Ophthalmol Retina; 2020 Jan; 4(1):57-66. PubMed ID: 31902472
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study.
    Boyer D; Heier J; Brown DM; Clark WL; Vitti R; Berliner AJ; Groetzbach G; Zeitz O; Sandbrink R; Zhu X; Beckmann K; Haller JA
    Ophthalmology; 2012 May; 119(5):1024-32. PubMed ID: 22440275
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A systematic review and meta-analysis to compare the efficacy of conbercept with ranibizumab in patients with macular edema secondary to retinal vein occlusion.
    Liu W; Li Y; Cao R; Bai Z; Liu W
    Medicine (Baltimore); 2020 May; 99(21):e20222. PubMed ID: 32481293
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES): six-month results of a prospective randomized clinical trial.
    Pielen A; Mirshahi A; Feltgen N; Lorenz K; Korb C; Junker B; Schaefer C; Zwiener I; Hattenbach LO;
    Acta Ophthalmol; 2015 Feb; 93(1):e29-37. PubMed ID: 25042729
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antivascular endothelial growth factors in the treatment of macular oedema secondary to central retinal vein occlusion: a meta-analysis.
    Zhou S; Gao J; Xu X
    Clin Exp Ophthalmol; 2014; 42(7):637-49. PubMed ID: 24330277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.